Baseline characteristics
| Control | Psoriatic arthritis | Rheumatoid arthritis | Psoriasis | ||||
|---|---|---|---|---|---|---|---|
| No DMARD | DMARD | No DMARD | DMARD | No DMARD | DMARD | ||
| N=81 573 | N=4174 | N=4532 | N=17 912 | N=23 840 | N=134 095 | N=4329 | |
| Demographics | |||||||
| Age (mean (SD)) | 49.86 (18.25) | 51.63 (14.95) | 49.80 (13.70) | 63.48 (16.15) | 59.76 (14.34) | 47.56 (17.73) | 49.27 (16.52) |
| Male N (%) | 36 806 (45.1) | 2121 (50.8) | 2329 (51.4) | 5185 (28.9) | 7129 (29.9) | 65 280(48.7) | 2201 (50.8) |
| Disease duration* (Mean years (SD)) | N/A | 5.75 (7.93) | 4.39 (6.92) | 8.70 (11.42) | 5.98 (8.78) | 7.10 (10.51) | 12.20 (12.04) |
| Cohort time (mean (SD)) | 5.24 (3.92) | 5.55 (4.02) | 5.02 (3.77) | 5.40 (3.99) | 5.36 (3.80) | 5.41 (3.99) | 4.33 (3.40) |
| Baseline event rates† | |||||||
| Myocardial infarction N (%) | 1925 (2.36) | 104 (2.49) | 88 (1.94) | 818 (4.57) | 983 (4.12) | 3193 (2.38) | 116 (2.68) |
| Stroke N (%) | 1265 (1.55) | 59 (1.41) | 48 (1.06) | 625 (3.49) | 531 (2.23) | 2015 (1.50) | 80 (1.85) |
| Transient ischaemic attack N (%) | 433 (0.53) | 20 (0.48) | 19 (0.42) | 209 (1.17) | 165 (0.69) | 627 (0.47) | 20 (0.46) |
Additional baseline characteristics are found in online supplementary table S1.
*Disease duration was calculated from the diagnosis date to start date.
†Note that patients with baseline event rates were excluded from the relevant analyses (eg, patients with a previous MI were excluded from the incident MI analysis and the composite outcome analysis).
DMARD, disease-modifying anti-rheumatic drug; MI, myocardial infarction.